Physician profile
Steven Wodzinski
NPI 1730185943
$2,862.16
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,862.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $781.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $582.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $233.68 | 2019 | |
| Mylan Specialty L.P. | $171.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $152.85 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $150.15 | 2019 | |
| Genentech USA, INC. | $139.16 | 2019 | |
| Electromed, INC. | $86.34 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.77 | 2019 | |
| Paratek Pharmaceuticals, INC. | $54.99 | 2019 | |
| Genzyme Corporation | $49.22 | 2019 | |
| Philips North America LLC | $32.42 | 2019 | |
| Circassia INC. | $25.81 | 2019 | |
| Advanced Respiratory, INC | $16.82 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.65 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $15.61 | 2019 | |
| Grifols USA, LLC | $15.16 | 2019 | |
| Merck Sharp & Dohme LLC | $13.42 | 2019 | |
| Insmed, INC. | $13.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Wodzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.